vTv Therapeutics Inc
VTVT
NASDAQ
Biotechnology
$30.12
USD
-0.73 (-2.37%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $125.18M
Volume 74.8K
Revenue
$36.84M
TTM
+216600.0%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-6.40M
TTM
+73.2%
YoY
Operating Cash Flow
$-16.76M
TTM
+23.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 36.8 | 0.0 |
YoY Growth | — | — | -100.0% | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 36.8 | 0.0 |
Selling, General & Administrative | 3.6 | 3.7 | 4.0 | 4.6 | 5.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
Total Operating Expenses | 7.7 | 10.7 | 8.0 | 13.6 | 13.9 |
Operating Income | -7.7 | -10.7 | -8.0 | 23.3 | -13.9 |
EBITDA | -7.7 | -10.7 | -8.0 | 23.3 | -13.9 |
Other Income / Expense | 0.1 | -0.0 | 0.0 | 0.0 | 0.1 |
Total Other Income / Expense | 0.3 | 0.4 | 0.9 | 0.9 | 0.9 |
Income Before Income Taxes | -7.4 | -10.3 | -7.1 | 24.1 | -13.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -7.4 | -10.3 | -7.1 | 24.1 | -13.1 |
Consolidated Net Income / Loss | -7.4 | -10.3 | -7.1 | 24.1 | -13.1 |
Net Income Attributable to Common Shareholders | -6.0 | -8.7 | -7.1 | 24.1 | -13.1 |
Basic EPS | -$0.92 | -$1.08 | -$0.57 | $1.94 | -$1.05 |
Diluted EPS | -$0.92 | -$1.08 | -$0.57 | $1.65 | -$1.05 |
Basic Shares Outstanding | 6.6M | 8.1M | 12.5M | 12.4M | 12.4M |
Diluted Shares Outstanding | 6.6M | 8.1M | 12.5M | 14.6M | 12.4M |